Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- Health Spend Management
- High-Deductible Health Plans
- (-) Impact on Outcome & Spending
- (-) Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 173 Results
Reference Pricing Isn’t Worth the Risk to Innovation and Patient Health
A Health Affairs Blog co-authored by NPC's Michael Ciarametaro explores the tradeoffs and risks associated with international reference pricing and suggests alternative policy approaches that…
Going Below The Surface
Going Below The Surface was an NPC-led initiative to broaden and improve the conversation around how we use health care resources in the United States.
NPC in Morning Consult: Biopharmaceutical Price Regulation - No Panacea for Patients
In a column published in Morning Consult, NPC's research team explains why potential government involvement in drug pricing would be unlikely to increase patient affordability.
Affordability Is About More Than Drug Prices
A research survey found that potential government involvement in drug pricing would be unlikely to increase patient affordability.
Celebrating the Use of Medicines in Keeping People Healthy
NPC President and CEO John O'Brien discusses how prescription medicines and the pharmacists who provided them helped people stay healthy at home during the pandemic.
The Budget Cap Dilemma: Can You Reduce Spending and Preserve Patient Health?
National Pharmaceutical Council (NPC) hosted a virtual panel discussion on state decisions to implement budget caps and the strategies, challenges, and the relevance of these decisions on patient…
Focus on Whole Person Quality Care When Implementing Budget Caps
The National Pharmaceutical Council hosted a virtual panel discussion on state decisions to implement budget caps and the strategies, challenges, and the relevance of these decisions on patient…
The Impact of COVID-19 on Real-World Health Data and Research
This white paper provides key health care stakeholders, including clinicians, researchers, payers and regulators, with a broad view of how the COVID-19 pandemic may have impacted real-world data (RWD…
U.S. vs. EU: Not a Direct Comparison When It Comes to Drug Pricing
It’s challenging to compare U.S. and ex-U.S. countries’ drug prices and health spending, given the big differences in the countries’ economies, health care systems, payment mechanisms and disease…
NPC Comments on Most Favored Nation (MFN) Model [CMS-5528-IFC]
NPC explains how using payment models based on pricing in other countries could have a negative impact on patient outcomes, access to treatments and future innovation.
Assessing Consumer and Employer Willingness to Pay for New Medical Technologies
This study examines whether health care consumers and large employers would be willing to continue to pay for new medical technologies associated with significant improvements in patient health…
NPC Weighs in on NQF’s Draft Report on Patient-Reported Outcomes
The National Pharmaceutical Council (NPC) submitted comments to the National Quality Forum (NQF) regarding the Patient-Reported Outcomes: Best Practices on Selection and Data Collection draft…
A Path of Her Own: Salama Freed, 2020-22 NPC/Duke-Margolis Health Policy Fellow
Salama Freed, PhD, has always wanted to learn about the inner-world of health policy – who shapes it, what drives it and how it gets done. She believes that her path to this experience is through the…
Do Patient Preferences Align with Value Frameworks? A Discrete-Choice Experiment of Patients with Breast Cancer
The study assessed patient preferences for aspects of breast-cancer treatments to evaluate the usual assumptions in scoring rubrics for value frameworks.
A Wish List for the Health Care Sector in 2020
NPC President and CEO Dan Leonard reflects on the health policy issues he hopes will be addressed in 2020.
NPC Weighs in on CMS Oncology Care First Model
NPC submitted comments regarding the Centers for Medicare and Medicaid Services Center for Medicare and Medicaid Innovation informal request for information on the Oncology Care First Model.
Three Themes You’ll Take Away From “Health Spending: Moving From Theory to Action”
Health spending is increasing in the United States, but what steps are being taken to address this challenge? Join Health Affairs and the National Pharmaceutical Council (NPC) on September 11 for an…